The review found no eligible studies for this question.
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
Inhaled corticosteroids (ICS) showed no clear difference in proportion with adverse effects of treatment compared with placebo (moderate certainty).
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
TNF‐α blockers intervention showed no clear difference in adverse effects after treatment initiation: infections compared with placebo or additional treatment (low certainty).
Metformin leads to higher adverse effects associated with the treatment: diarrhoea compared with placebo (high certainty).
Zonisamide may leads to higher adverse effects: ataxia (whole treatment period; any dose) compared with placebo (low certainty).
Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).
Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).
TNF‐α blockers intervention may leads to lower adverse effects after treatment initiation: infusion reactions compared with placebo or additional treatment (low certainty).
It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).
Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).
It is very uncertain whether antidepressant changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with placebo (very low certainty).
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions (rash) compared with placebo or additional treatment (very low certainty).
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
It is very uncertain whether lamotrigine changes any reported adverse effects up to 12 weeks after starting treatment… compared with placebo (very low certainty).